Dosing ribavirin in hepatitis E-infected solid organ transplant recipients

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis E virus (HEV) is a leading cause of viral hepatitis globally.
• HEV genotypes 1 and 2 are common in developing nations, while genotypes 3 and 4 prevail in developed countries.
• While often self-limiting, HEV can cause chronic hepatitis, cirrhosis, and extra-hepatic manifestations in immunocompromised individuals.

Purpose of the Study:

• To review the epidemiology, transmission, and clinical features of HEV.
• To examine the current treatment of chronic HEV, focusing on ribavirin therapy.
• To highlight unmet needs in ribavirin treatment for chronic HEV.

Main Methods:

• Literature review of HEV epidemiology and clinical manifestations.
• Analysis of ribavirin efficacy in treating chronic HEV.
• Discussion of ribavirin pharmacokinetics, dosing, and therapeutic drug monitoring.

Main Results:

• Ribavirin is effective in treating chronic HEV, achieving sustained virological response in 80-85% of patients.
• Reduction of immunosuppression is the primary therapeutic approach when feasible.
• The exact mechanism of action for ribavirin and the impact of HEV RNA polymerase mutations remain unclear.

Conclusions:

• Chronic HEV requires effective treatment strategies, with ribavirin being a key option.
• Further research is needed to optimize ribavirin dosing, duration, and therapeutic drug monitoring for chronic HEV.
• Understanding ribavirin's pharmacokinetics and potential drug interactions is crucial for improving patient outcomes.